Trial Profile
Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinence.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Aug 2022
Price :
$35
*
At a glance
- Drugs Cizolirtine (Primary) ; Tolterodine
- Indications Urge incontinence
- Focus Adverse reactions; Therapeutic Use
- Sponsors Esteve
- 30 Jul 2022 Status changed from recruiting to completed.
- 14 Jun 2011 New trial record